Vadodara: Alembic Pharmaceuticals Limited has announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Alcaftadine Ophthalmic Solution, 0.25% (OTC).

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Lastacaft Solution, 0.25%, of AbbVie Inc.

Alcaftadine Ophthalmic Solution, 0.25% (OTC) is used to temporarily relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander. 

Alembic has a cumulative total of 216 ANDA approvals (189 final approvals and 27 tentative approvals) from USFDA.Medical Dialogues team had earlier reported that the Company had received final approval from the USFDA for its ANDA for Bromfenac Ophthalmic Solution, 0.07%.Read also: Alembic Pharma bags USFDA nod for Bromfenac Ophthalmic SolutionAlembic Pharmaceuticals Limited is a vertically integrated research and development pharmaceutical company. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA. Read also: Alembic Pharma secures USFDA nod for Seizure treatment drug Lamotrigine ER

Countries of the Americas agree on new strategy to strengthen tobacco control

Cristina Mitchell

3 Oct 2024

View the full post Authentic Caribbean Foundation and Partners disability conference in Grenada on NOW Grenada.

Santo Domingo.- The Public Prosecutor’s Office has presented a report from the Comptroller General of the Republic as evidence in the Second Collegiate Court of the National District, highlighting irregularities in payments exceeding 310 million pesos related to purchasing processes during Wilfredo (Freddy) Hidalgo Núñez’s time as Minister of Public Health in 2013. Hidalgo is accused of being part of a corruption scheme that misappropriated over 4,500 million pesos, uncovered during Operation Pulpo.

Prosecutor Ernesto Guzmán Alberto indicated that Hidalgo improperly requested payment exemptions from the then-Comptroller General, Rafael Germosén. Auditor Amisael Félix Vicioso testified that the payment releases lacked the required signatures and did not comply with Law 340-06 on Purchases and Contracts. Irregularities included a lack of public bidding, improper timing of purchase authorizations, and no formal contracts for the transactions.

Witnesses, including auditors Rosa Iris Fanis and Carmen Magalys Baltazar Carpio, noted significant legal violations in the purchasing processes. The court has scheduled the next hearing for October 7, where the defense will continue cross-examining the witnesses.

Activity surrounding the largest walk-for-a-cause in the Eastern Caribbean is intensifying, as plans are confirmed for the Walk for the Cure.

Interest is high from corporate sponsors and their staff who are ready to take part in the walk, as well as the numerous vendors who will be on hand for the expected 20 000 people who will be either walking or running for the Breast Screening Programme of the Barbados Cancer Society.

Many of the sponsors and vendors were on hand for a recent site visit to see where they would physically set up their tents and banners and also get a final briefing on the route which starts at Warrens again this year.

(PR)

The post Preparations ramp up ahead of Walk for the Cure appeared first on Barbados Today.